Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | XBP1 | P17861 | 2/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489817 | 1.00 | CASP1 (0.43) | CASP1P2RX7PARP1JAK2LMNA | |
| SCHEMBL3663477 | 0.84 | SMO (0.39) | P2RX7LMNASMOTUBB4ATUBB | |
| SCHEMBL30586206 | 0.84 | KEAP1 (0.46) | LMNASMOTUBB4ATUBBTUBA3C | |
| SCHEMBL165279 | 0.84 | KEAP1 (0.46) | LMNASMOTUBB4ATUBBTUBA3C | |
| SCHEMBL30489829 | 0.84 | SMO (0.39) | P2RX7LMNASMOTUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL23500735 | 0.82 | KEAP1 (0.44) | LMNASMOTUBB4ATUBBTUBA3C | |
| SCHEMBL19616100 | 0.82 | TUBB4A (0.41) | LMNASMOTUBB4ATUBBTUBA3C | |
| SCHEMBL17268296 | 0.82 | NNMT (0.41) | CASP1PARP1KMT2AATMGAA | |
| SCHEMBL4191868 | 0.80 | IKBKB (0.42) | CASP1P2RX7PARP1JAK2LMNA | |
| SCHEMBL3633773 | 0.80 | P2RX7 (0.40) | CASP1P2RX7PARP1JAK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959863-A | Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine | ISHIHARA SANGYO KAISHA | 2011-01-26 | — | — | CN | claimed |
| EP-2251329-A1 | PROCESS FOR PRODUCTION OF 3-AMINO-2-CHLORO-6- TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-11-17 | — | — | EP | claimed |
| WO-2026103888-A1 | PYRIMIDIN-2(1H)-ONE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海青润医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-122036626-A | Pyrimidine-2 (1H) -ketone derivative, pharmaceutical composition and application thereof | 上海青润医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-02-06 | — | — | US | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-4419506-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-08-28 | — | — | EP | disclosed |
| CN-118434722-A | Methionine adenosyltransferase 2A (MAT 2A) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118265700-A | Substituted naphthyridinone derivative, pharmaceutical composition and application thereof | 上海海雁医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2009110475-A1 | PROCESS FOR PRODUCTION OF 3-AMINO-2-CHLORO-6- TRIFLUOROMETHYLPYRIDINE | 石原産業株式会社 (JP) | 2009-09-11 | — | — | WO | disclosed |
| CN-101265228-A | Method for preparing 2-chloro-3-trichloromethyl-6-trifluoromethylpyridine | SHANGHAI RECORD PHARMACEUTICAL (CN) | 2008-09-17 | — | — | CN | disclosed |
| CN-101265228-A | Method for preparing 2-chloro-3-trichloromethyl-6-trifluoromethylpyridine | SHANGHAI RECORD PHARMACEUTICAL (CN) | 2008-09-17 | — | — | CN | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1753429-A1 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1882568-A | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | CASP1 4630/4885P2RX7 4178/4885PARP1 2986/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | CASP1 4330/4885P2RX7 163/4885PARP1 2655/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | CASP1 4328/4885P2RX7 3304/4885PARP1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.